{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:20:25Z","timestamp":1793431225131,"version":"4.5.0"},"reference-count":16,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monitoring of measurable residual disease (MRD) is essential to the management of acute lymphoblastic leukemia (ALL) and is typically performed through repeated bone marrow (BM) assessments. Using a next-generation sequencing (NGS) MRD platform, we performed a prospective observational study evaluating the correlation between peripheral blood (PB) and BM MRD in adults with ALL receiving cellular therapies (hematopoietic cell transplantation [HCT] and chimeric antigen receptor T-cell [CAR-T] therapies). Among the study cohort (N = 69 patients; 126 paired PB\/BM samples), we found strong correlation between PB and BM MRD (r = 0.87; P &amp;lt; .001), with a sensitivity and specificity of MRD detection in the PB of 87% and 90%, respectively, relative to MRD in the BM. MRD became detectable in the PB in 100% of patients who subsequently relapsed following HCT, with median time from MRD+ to clinical relapse of 90 days, and in 85% of patients who relapsed following CAR T, with median time from MRD+ to clinical relapse of 60 days. In adult patients with ALL undergoing cellular therapies, we demonstrate strong concordance between NGS-based MRD detected in the PB and BM. Monitoring of ALL MRD in the PB appears to be an adequate alternative to frequent invasive BM evaluations in this clinical setting.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004234","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T11:38:23Z","timestamp":1629459503000},"page":"3147-3151","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori","family":"Muffly","sequence":"first","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Sundaram","sequence":"additional","affiliation":[{"name":"Department of Medicine, Quantitative Sciences Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Yurkiewicz","sequence":"additional","affiliation":[{"name":"Division of Hematology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Medicine Stanford University, Stanford CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Burnash","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Y.","family":"Spiegel","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-4172","authenticated-orcid":false,"given":"Sally","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett H.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-0358","authenticated-orcid":false,"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Shizuru","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-5850","authenticated-orcid":false,"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Division of Hematology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyma T.","family":"Vempaty","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Santa Clara, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"issue":"7","key":"2021082015375732000_B1","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol."},{"key":"2021082015375732000_B2","author":"NCCN Clinical Practice Guidelines in Oncology"},{"issue":"16","key":"2021082015375732000_B3","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2018-12-852376","article-title":"Taking a \u201cBiTE out of ALL\u201d: blinatumomab approval for MRD-positive ALL","volume":"133","author":"Curran","year":"2019","journal-title":"Blood."},{"issue":"15","key":"2021082015375732000_B4","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","article-title":"Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial","volume":"32","author":"Ribera","year":"2014","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021082015375732000_B5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.25338","article-title":"Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts","volume":"94","author":"Short","year":"2019","journal-title":"Am J Hematol."},{"issue":"12","key":"2021082015375732000_B6","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood."},{"issue":"9","key":"2021082015375732000_B7","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbmt.2014.04.018","article-title":"Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival","volume":"20","author":"Logan","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2021082015375732000_B8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer."},{"issue":"1","key":"2021082015375732000_B9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/hematology.2019000008","article-title":"Navigating the nexus of MRD and novel agents in ALL","volume":"2019","author":"Advani","year":"2019","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"1","key":"2021082015375732000_B10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.seminoncol.2011.11.009","article-title":"Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle","volume":"39","author":"Br\u00fcggemann","year":"2012","journal-title":"Semin Oncol."},{"key":"2021082015375732000_B11","first-page":"blood.2020006219","article-title":"Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood versus bone marrow [published online ahead of print 7 October 2020]","author":"Godwin","journal-title":"Blood."},{"issue":"18","key":"2021082015375732000_B12","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/bloodadvances.2020002306","article-title":"Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing","volume":"4","author":"Lucas","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2021082015375732000_B13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/hematology.2019000013","article-title":"Prognostication with circulating tumor DNA: is it ready for prime time?","volume":"2019","author":"Kurtz","year":"2019","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"12","key":"2021082015375732000_B14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","article-title":"ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper","volume":"17","author":"Dasari","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"issue":"4","key":"2021082015375732000_B15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccell.2020.03.012","article-title":"Liquid biopsy-based biomarkers of treatment response and resistance","volume":"37","author":"Kilgour","year":"2020","journal-title":"Cancer Cell."},{"issue":"4","key":"2021082015375732000_B16","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41375-019-0599-1","article-title":"Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia","volume":"34","author":"Kotrova","year":"2020","journal-title":"Leukemia."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/16\/3147\/1818405\/advancesadv2021004234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/16\/3147\/1818405\/advancesadv2021004234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T11:38:36Z","timestamp":1629459516000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/16\/3147\/476581\/Concordance-of-peripheral-blood-and-bone-marrow"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":16,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,8,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004234","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}